Lactylation in cancer: Advances and opportunities for treatment resistance

Keke Xu, Yi Shou, Ruiqi Liu, Hao Xiong, Xiaomeng Dai, Xuanwen Bao, Xiaohong Chen, Luanluan Huang, Hailong Sheng, Haibo Zhang, Yanwei LüClinical 2025 · DOI

TL;DR

This review explores lactylation, a recently discovered post-translational modification, and its critical role in driving cancer treatment resistance across various therapies. The authors highlight how targeting lactylation pathways offers promising new strategies to overcome this resistance and improve patient outcomes.

What Problem Does This Paper Address?

Cancer treatment resistance is a major hurdle in oncology, leading to treatment failure and recurrence. While various mechanisms contribute to this resistance, the role of metabolic reprogramming in cancer cells, particularly the Warburg effect and subsequent lactate production, has become increasingly apparent. This paper delves into how lactate, beyond its metabolic role, acts as a substrate for lactylation, a post-translational modification that significantly impacts gene expression and protein function. The authors address the critical question of how aberrant lactylation contributes to resistance against chemotherapy, immunotherapy, targeted therapy, and radiotherapy, and explore potential therapeutic avenues to counteract these effects.

Methods

This paper is a review article, meaning it synthesizes existing research rather than presenting new experimental data. The authors' "methods" involve a comprehensive literature search and critical analysis of published studies on lactylation in cancer. They discuss various experimental approaches used in the cited research, including:

  • Biochemical assays: To identify and quantify lactylation, and to study the activity of lactylation "writers" (enzymes that add lactyl groups) and "erasers" (enzymes that remove them).
  • Molecular biology techniques: Such as gene expression analysis, Western blotting, and immunoprecipitation to understand how lactylation affects protein function and gene regulation.
  • Cell-based assays: To investigate the impact of lactylation on cancer cell behavior, including proliferation, invasion, metastasis, and drug resistance.
  • In vivo studies: Using animal models to evaluate the therapeutic potential of targeting lactylation.
  • Clinical data analysis: Examining correlations between lactylation markers and patient outcomes.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Lactylation as a metabolic-epigenetic bridge: Lactate, a byproduct of the Warburg effect, is not just a metabolic fuel but also a direct substrate for lactylation, linking cellular metabolism to epigenetic regulation.
  • Aberrant lactylation fuels resistance: Dysregulated lactylation is a common denominator across various cancer therapies, contributing to resistance by enhancing DNA repair, promoting epithelial-mesenchymal transition (EMT), upregulating drug efflux pumps (ABC transporters), and modulating immune responses.
  • Targeting lactylation offers a multi-pronged approach: Inhibiting lactylation "writers" or "erasers," or targeting lactate production and transport, can restore sensitivity to existing therapies.
  • The TME is a key battleground: Lactylation within the tumor microenvironment (TME) influences immune cell function and polarization, contributing to immune evasion and resistance to immunotherapy.
  • Crosstalk with other PTMs is crucial: Lactylation doesn't act in isolation; it interacts with other post-translational modifications like acetylation, creating complex regulatory networks that impact cancer progression and resistance.

Key Results

The review highlights that lactylation has been shown to:

  • Enhance DNA damage repair: Specifically, lactylation of proteins like NBS1 and MRE11 promotes homologous recombination repair, making cancer cells more resistant to DNA-damaging agents like cisplatin.
  • Drive multidrug resistance: Lactylation can upregulate the expression of ABC transporters, leading to increased drug efflux from cancer cells.
  • Promote EMT: Lactylation is implicated in the EMT process, which is crucial for cancer metastasis and resistance.
  • Mediate immunosuppression: Lactylation in immune cells (e.g., macrophages, T cells) can lead to M2 polarization, immune evasion, and resistance to immunotherapy.
  • Restore sensitivity to therapies: Preclinical studies demonstrate that inhibiting lactylation can re-sensitize resistant cancer cells to chemotherapy, targeted therapy, and immunotherapy. For example, inhibiting H3K18la restored cisplatin sensitivity in resistant epithelial cells.

Limitations and Future Work

The authors acknowledge several limitations and suggest future directions:

  • Translational gap: While preclinical studies show promise, the clinical validation of lactylation-targeted therapies is still in its early stages. More clinical trials are needed to establish efficacy and safety.
  • Specificity of lactylation: It remains unclear whether lactylation-induced resistance is specific to certain cancer types or broadly applicable across various malignancies.
  • Complex interplay with other PTMs: The intricate balance between lactylation and other post-translational modifications (like acetylation) needs further elucidation to develop effective combination strategies.
  • Developing novel therapeutic agents: Future research should focus on developing more precise lactylation inhibitors and exploring novel approaches like targeting lactate oxidase (LOx) and PROTACs for more effective therapeutic interventions.
  • Understanding the TME: Further investigation into the precise mechanisms of lactylation in the TME and its impact on immune cell dysfunction is crucial for optimizing immunotherapy strategies.

Summary updated

Abstract

Lactylation links glycolysis to tumor progression and therapeutic response. Modulating lactylation writers and erasers restores treatment sensitivity. Aberrant lactylation drives resistance tomultiple cancer therapies. Crosstalk with other post-translational modifications suggests novel combination strategies.
BibTeX
@inproceedings{xu2025lactylation,
  author = {Keke Xu and Yi Shou and Ruiqi Liu and Hao Xiong and Xiaomeng Dai and Xuanwen Bao and Xiaohong Chen and Luanluan Huang and Hailong Sheng and Haibo Zhang and Yanwei Lü},
  title = {{Lactylation in cancer: Advances and opportunities for treatment resistance}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1002/ctm2.70478},
}
Figure